Phaseline

Targets › EZH2

EZH2 (Histone-lysine N-methyltransferase EZH2): drug programs, companies and trials

9 programs from 9 companies in 34 trials: 20 Phase 1, 12 Phase 2, 2 Phase 3; Oncology; next expected readout Feb 2027.

Catalytic subunit of the PRC2/EED-EZH2 complex, a Polycomb group (PcG) complex that methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. (UniProt, Q15910)

Open in Phaseline: the race on EZH2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
EpizymeTazemetostat
Histone-lysine N-methyltransferase EZH2 inhibitor
EZH2Phase 3Relapsed/Refractory Follicular Lymphoma; Peripheral Nerve Sheath Tumor; B-Cell Non-Hodgkin Lymphoma; Grade 3b Follicular Lymphoma …Feb 2027
Evopoint BiosciencesXNW5004 tablets
EZH2 inhibitor
EZH2Phase 3Relapsed/Refractory Peripheral T Cell Lymphoma; Follicular Lymphoma, Grade 1; Metastatic Castrate-Resistant Prostate CancerJul 2027
National Cancer Institute (NCI)Tazemetostat Hydrobromide
Histone-lysine N-methyltransferase EZH2 inhibitor
EZH2Phase 2Recurrent Endometrial Endometrioid Adenocarcinoma; Clinical Stage IV Cutaneous Melanoma AJCC v8; Extensive Stage Lung Small Cell Carcinoma; Recurrent B-Cell Non-Hodgkin Lymphoma …Feb 2027
Fudan UniversitySHR-2554
EZH2 inhibitor
EZH2Phase 2Relapsed/Refractory Peripheral T Cell LymphomaFeb 2027
The First Affiliated Hospital of Zhengzhou UniversitySHR2554
EZH2 inhibitor
EZH2Phase 2Advanced Gastric CancerJul 2027
Daiichi SankyoValemetostat Tosylate
EZH1/2 dual inhibitor
EZH1, EZH2, KDM1APhase 2Relapsed/Refractory Peripheral T-Cell Lymphoma; Non-small Cell Lung Cancer; Advanced Solid Tumor; Lymphoma, B-Cell …Mar 2028
Hanmi Pharmaceutical CompanyHM97662
EZH1/2 dual inhibitor
EZH1, EZH2Phase 1Advanced or Metastatic Solid TumorsJan 2028
Lan CoffmanCPI-0209
EZH2 inhibitor
EZH2Phase 1Recurrent Ovarian CancerJul 2028
NovartisTulmimetostat (DZR123, CPI-0209)
Dual EZH1/EZH2 inhibitor
EZH1, EZH2Phase 1Progressive Metastatic Castrate Resistant Prostate Cancer; Advanced Solid Tumor; Metastatic Hormone-Sensitive Prostate Cancer (mHSPC); Mycosis FungoidesNov 2029

Conditions

Follicular Lymphoma (3) Advanced Solid Tumor (2) Relapsed/Refractory Peripheral T Cell Lymphoma (2) Progressive Metastatic Castrate Resistant Prostate Cancer (1) Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (1) Mycosis Fungoides (1) Recurrent Endometrial Endometrioid Adenocarcinoma (1) Clinical Stage IV Cutaneous Melanoma AJCC v8 (1) Extensive Stage Lung Small Cell Carcinoma (1) Recurrent B-Cell Non-Hodgkin Lymphoma (1) Locally Advanced Urothelial Carcinoma (1) Follicular Lymphoma, Grade 1 (1)

Modalities

small molecule (7), mixed (2)

Companies

Novartis (1) National Cancer Institute (NCI) (1) Evopoint Biosciences (1) Lan Coffman (1) Epizyme (1) Daiichi Sankyo (1) Fudan University (1) The First Affiliated Hospital of Zhengzhou University (1) Hanmi Pharmaceutical Company (1)

Related targets

EZH1 (3) KDM1A (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.